Indications and mechanism analysis of platinib

Platinib, as an innovative drug, is mainly used to treat cancers related to RET (Rearranged during Transfection) gene mutations or fusions. Specifically, its indications include:

1.Adult patients with rearranged transfection(RET)gene fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). For these patients, platinib can be an effective treatment, especially when other treatments, such as chemotherapy, are ineffective.

2.Adult and pediatric patients 12 years old and above with advanced or metastatic RETmutant medullary thyroid carcinoma (MTC) requiring systemic treatment. Platinib can target the RET gene mutation and inhibit the proliferation and spread of cancer cells, thus prolonging the survival of patients.

3.Adults and pediatric patients 12 years old and above with advanced or metastatic RETfusion-positive thyroid cancer that require systemic treatment and are refractory to radioactive iodine. Platinib provides a new treatment option for these patients who are difficult to treat with traditional methods.

Platinib is a receptor tyrosine kinaseRET inhibitor. Platinib can specifically bind to the RET receptor and prevent its phosphorylation reaction, thus blocking the conduction of the RET signaling pathway. This process is critical for inhibiting the proliferation of cells expressing mutations in the RET gene.

Platinib is significantly more selective for RET than approved multikinase inhibitors. This means that while it inhibits cancer cells, it is less toxic to normal cells, thereby reducing the occurrence of side effects. Platinib is expected to prevent the occurrence of clinical drug resistance by inhibiting primary and secondary mutations. This has important implications for cancer patients undergoing long-term treatment.